Clinical Research Directory
Browse clinical research sites, groups, and studies.
Good-first: B/F/TAF As First-line ART
Sponsor: Affiliated Hospital of Nantong University
Summary
This is a multicohort study conducted at Affiliated Hospital of Nantong University, and Nantong Third Peoples Hospital (Designated Hospital for HIV/AIDS Treatment of Nantong City), China. The study would involve 630 patients initiating HIV treatment, divided into six cohorts. The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.
Official title: Good-first: a Multicohort Study of B/F/TAF As First-line ART in a Public Hospital in Eastern China
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
630
Start Date
2024-07-01
Completion Date
2026-06-30
Last Updated
2024-10-01
Healthy Volunteers
No
Conditions
Interventions
B/F/TAF
Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
TDF+3TC+EFV
Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
DTG/3TC
Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
Locations (1)
Nantong Third Peoples Hospital
Nantong, Jiangsu, China